Kornimate/medical-research-clean huggingface dataset:
bci post-stroke neurorehabilitation

Conditions: Poststroke/CVA Hemiparesis; Paralytic Stroke; Hand Flaccid Paralysis

Summary: the goal is to evaluate the potential of a eeg based bci (brain-computer-interface) connected to a non-invasive pneumatic glove for rehabilitation of hand-movements post-stroke.

brain computer interfaces (bci) encompasses the usage of the brain signals to compensate for lost physical function. the current protocol evaluates the therapeutic potential of a eeg based driven bci that is connected to a non-invasive pneumatic glove for rehabilitation of hand flexion/extension post-stroke. the system non-invasive, portable and low-cost. the utility and usability of the system will be investigated at two levels. first by means of questionnaires for patients and therapist and second by means of in depth analysis of the eeg signals during intended, imagined and passive driven hand movements in relation to no movement at all and the capacity of the bci to distinguish between these conditions.

Eligibility criteria:
inclusion criteria: * \> 6 months post-stroke (chronic), unilateral * \> 18 yrs * little to no hand movement * spasticity \< 3 on modified ashworth scale exclusion criteria: * major cognitive deficits (folstein mini mental status \> 23 * strong hemi-neglect (catherine bergego scale \> 15/30)

Keywords: post stroke bci reeducation hand movement
pre emptive analgesics for pain relief in impacted lower third molar surgery

Conditions: Impacted Third Molar Tooth

Summary: the purpose of the study is to evaluate the efficacy of pre-emptive paracetamol in reducing intra operative pressure and post operative pain after surgical removal of impacted mandibular third molar using visual analogue scale


Eligibility criteria:
inclusion criteria: * patients aged 21 years and above * healthy patients (asa i) * patients who are not allergic to the drugs and local anesthetic agents used exclusion criteria: * patients who are on concurrent treatment with nsaids or corticosteroids * patients with pericoronitis or periapical infection
exercises and performance anxiety among young instrumentalists.

Conditions: Musculoskeletal Pain; Performance Anxiety

Summary: the purpose of this study is to assess the impact of an original exercise program intended for students of the university of music on dealing with stage fright and its psychophysical symptoms.

the study group covers students of a music university who play various musical instruments. participants will be divided into the experimental and control groups. the study duration is scheduled to be 6 weeks. the control group will not have any intervention. the experimental group will undertake 45 mins exercise classes twice a week. each exercise session will consist of an initial part (warm-up), a main part with exercises designed to strengthen the postural muscles and stretch the contracted muscle groups that are especially prone to pain in musicians (back and upper limbs), and a final part of calming and breathing exercises. at the beginning and at the end of the study, participants of both groups will be asked to complete a polish version of validated psychological questionnaires: kenny music performance anxiety inventory-revised, ogińska-bulik's \& juczyński's resiliency assessment scale (spp-25), musculoskeletal pain intensity and interference questionnaire for musicians of the polish population (mpiiqm-p) and one original questionnaire assessing the stress level before, during and after a performance. all participants will also undergo physical examination. a measurement of the range of motion of trunk flexion in standing (cm) and the algometric measurement of the pain threshold (kg/cm2) of selected back muscles (trapezius muscles, upper and lower and levator scapula) on the right and left sides of the body. algometric measurements will be made using the pain test fpx algometer algometer (wagner). statistical analysis. the variables will be coded and analyzed using the statistica program. baseline demographics will be compared between groups (independent t-tests, chi-square tests). two-way mixed-model analyses of variance (anova) will explore the effect of the exercise program on symptoms and anxiety.

Eligibility criteria:
inclusion criteria: * playing on a musical instrument for at least 5 years * age 18 to 35 * consent to participate in the study * participation in at least 8 meetings (exercise) within 6 weeks exclusion criteria: * current (last 3 months) locomotor injuries (fractures, sprains, dislocations), medical contraindications to exercise, confirmed by a medical opinion * neurological and oncological diseases confirmed by a medical diagnosis * previous spine surgeries, scoliosis confirmed by radiograph (\<10ᵒ cobb) * regular intake of muscle relaxants, painkillers, anti-inflammatory drugs, anti-depressants * age under 18 or over 35 * no consent to participate in the study to participate in the study.

Keywords: occupational stress musculoskeletal pain performance anxiety occupational diseases exercise therapy
a pilot study of the effects of highly active antiretroviral therapy on kaposi's sarcoma in zimbabwe

Conditions: AIDS-related Kaposi's Sarcoma

Summary: open-label study of a regimen of antiretrovirals for the treatment of aids-ks. this study will be conducted at a single site, the parirenyatwa hospital ks clinic. step 1 was conducted to determine the extent of clinical resolution of aids-ks disease in response to treatment with antiretroviral therapy and to investigate whether clinical resolution of ks is associated with suppression of kshv replication. step 2 was developed to then evaluate the clinical, immunological, and virological effects of a switch from a twice-daily all-nucleoside reverse transcriptase inhibitor (nrti) antiretroviral regimen to a once-daily regimen of 2 nrtis plus a ritonavir-boosted protease inhibitor in persons with aids-ks and good virologic suppression an all nrti regimen. step 3 was included to evaluate the clinical, immunological, and virological effects of intensification with a ritonavir-boosted protease inhibitor in persons with aids-ks who have virological failure on an all nrti regimen.

to identify factors associated with successful treatment of ks with antiretroviral therapy and to determine if highly active antiretroviral therapy improves survival and quality of life for persons with aids-ks in zimbabwe. a secondary objective is to investigate the durability of hiv-1 suppression by the combination of abc/3tc/zdv in persons infected with hiv-1 subtype c and to evaluate the timing and characteristics of mutations in hiv-1 reverse transcriptase in subjects who fail to achieve, or to maintain suppression of hiv-1 replication during treatment with abc/3tc/zdv. an important objective is to assess adherence to a simplified antiretroviral regimen in a resource-limited setting. the study will evaluate the clinical, immunological, and virological effects of a switch from a twice-daily all-nucleoside reverse transcriptase inhibitor (nrti) antiretroviral regimen to a once-daily regimen of 2 nrtis plus a ritonavir-boosted protease inhibitor in persons with aids-ks and good virologic suppression on abc/3tc/zdv (see above).

Eligibility criteria:
inclusion criteria:completion of at least 96 weeks of treatment with abc/3tc/zdv on protocol step 1. * currently receiving abc/3tc/zdv on step 1/initial open-label allnrti phase of study. * plasma hiv-1 rna \< 400 copies/ml on the most recent plasma hiv-1 rna performed within 4 weeks of step 2 entry. * willing to potentially switch to a new antiretroviral regimen. * in the opinion of the site investigator currently has clinical evidence of active ks disease. exclusion criteria * none

Keywords: aids-related kaposi's sarcoma antiretroviral therapy
a study to evaluate the efficacy of lastacaft® compared to pataday™ and placebo in patients with acute allergic conjunctivitis

Conditions: Conjunctivitis, Allergic

Summary: this study will evaluate the efficacy of lastacaft® (alcaftadine 0.25%) and pataday™ (olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.


Eligibility criteria:
inclusion criteria: * history of ocular allergies within the past 24 months. * able to avoid wearing contact lenses for at least 72 hours prior to and during the study trial period. exclusion criteria: * any presence of active ocular infection or history of an ocular herpetic infection. * ocular surgery within 3 months prior to the first visit or refractive surgery within the past 6 months. * have any planned surgery during the study or 30 days after the study.
clinical trial to assess safety, tolerability and the pharmacodynamic effect of different concentrations of a new anti-inflammatory substance in subjects with chronic plaque psoriasis

Conditions: Psoriasis Vulgaris

Summary: to assess safety and tolerability after treatment with leo 134310 cutaneous solution.


Eligibility criteria:
inclusion criteria: * subjects aged 18-64 years (inclusive) with plaque psoriasis in a chronic stable phase. * men or women of non-child bearing potential. exclusion criteria: * acute psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, pustular, exfoliative or inverse psoriasis. * according to defined washout periods: topical antipsoriatic drugs (except salicylic acid in petroleum jelly); systemic antipsoriatics and biologics; ultraviolet (uv) therapy.
cabozantinib and nivolumab among older patients with renal cell carcinoma

Conditions: Kidney Cancer; Renal Cell Cancer

Summary: the goal of the study is to describe real-life use and exposition to nivolumab-cabozantinib among older patients with metastatic clear-cell renal cell cancer

this study will be a prospective, multicentric, single-arm cohort. patients will receive nivolumab-cabozantinib association per standard. all patients will benefit of geriatric evaluation (g-code) at inclusion, and a multimodal and reinforced follow-up, including medical oncologist, geriatrician nurse of doctor, phone calls, and optional pharmacological follow-up for cabozantinib.

Eligibility criteria:
inclusion criteria: 1. patients ≥ 70 years-old 2. confirmed advanced or metastatic renal-cell carcinoma 3. patients not previously treated in metastatic setting 4. performance status 0 to 2 5. sexually active male patients must agree to use condom during the study and for at least 5 months after the last study treatment administration. also, it is recommended their women of childbearing potential partner use a highly effective method of contraception. 6. patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. patient should be able and willing to comply with study visits and procedures as per protocol. 7. patients must be affiliated to a social security system or beneficiary of the same exclusion criteria: 1. participation in another clinical study with an investigational product during the last four weeks and while on study treatment (patients may be included in cabold if they are included in the arm b of care1 study euct n° 2023-503317-29-00) 2. performance status \> 2 3. any condition that represent a contraindication to cabozantinib and/or nivolumab, as described in summaries of products characteristics, including symptomatic untreated brain metastasis or active auto-immune disease requiring systemic immunosuppressant/modulator (thyroid or adrenal disorder are not an exclusion criteria) 4. any severe cardiovascular or thrombo-embolic event in the last three months 5. any situation for which exclusive palliative care intervention is recommended 6. patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent

Keywords: renal cell carcinoma kidney cancer cabozantinib nivolumab elderly patients geriatric population
oxidative and antioxidant indices to hiit and aloe vera supplementation in patients with t2dm

Conditions: Diabetes Type 2

Summary: diabetes is a prevalent metabolic disease that leads to increased blood sugar levels due to insulin shortage or resistance. type 2 diabetes is often linked to obesity, which can increase insulin resistance. meteorin-like protein (metrnl) is a new secreted protein that affects insulin sensitivity and has been found to be negatively related to serum glucose levels in people with diabetes. oxidative stress in diabetics can stimulate the production of inflammatory mediators, increasing the activity of the antioxidant system. aloe vera, a widely used plant, has been used for treating diabetes, wound healing, tumors, and inflammatory bowel disease. it has anti-inflammatory, antioxidant, neuroprotective, antidepressant, and memory-enhancing effects. exercise can improve diabetic patients' conditions by increasing the expression of glut4 protein and skeletal muscle. high-intensity interval training has been shown to increase the expression of the metorin gene in human subjects and decrease mda in type 2 diabetic patients. however, no studies have examined the simultaneous effect of exercise and aloe vera on diabetes indicators. the present study aims to investigate the response of metrnl and some oxidative and antioxidant plasma indicators to high-intensity interval training and aloe vera supplementation in type 2 diabetic men. the findings indicate that exercise and consumption of plants with anti-inflammatory and antioxidant properties can be effective in modulating the pathological effects of diabetes and increasing insulin sensitivity.


Eligibility criteria:
inclusion criteria: * male participants who have been diagnosed with t2dm at least 3 months prior to the start of the study according to standard criteria * inactive participants according to the international physical activity questionnaire (ipaq) * participants receiving stable medical therapy for t2dm, excluding those on exogenous insulin therapy * participants who were free from injuries or chronic health conditions that could limit their ability to safely participate in an intense exercise program were included in the study exclusion criteria: * fasting glucose above 270 mg / dl * exogenous insulin * history of diabetic complications (the final stage of proliferative diabetic retinopathy, or subsequent overt nephropathy, diabetic ketoacidosis, or severe diabetic neuropathy) * hereditary glucose and galactose malabsorption

Keywords: exercise, blood glucose oxidative stress, diabetes mellitus
subcutaneous cinryze with recombinant human hyaluronidase for prevention of angioedema attacks

Conditions: Hereditary Angioedema (HAE)

Summary: the primary objectives of the study are to evaluate the safety, tolerability, and efficacy of two doses of cinryze with recombinant human hyaluronidase (rhuph20) administered by subcutaneous (sc) injection to prevent angioedema attacks.


Eligibility criteria:
inclusion criteria: * be ≥12 years of age. * have a confirmed diagnosis of hereditary angioedema. exclusion criteria: * receipt of any c1 inhibitor (c1 inh) therapy or any blood products for treatment or prevention of an angioedema attack within 7 days before the first dose of study drug. * be receiving prophylactic intravenous cinryze that exceeds 1000 units every 3 or 4 days (maximum weekly dose 2000 units). * have received any androgen therapy (e.g., danazol, oxandrolone, stanozolol, testosterone) within 7 days prior to the first dose of study drug. * if female, have started taking or changed the dose of any hormonal contraceptive regimen or hormone replacement therapy (i.e., estrogen/progestin containing products) within 3 months prior to the first dose of study drug. * history of allergic reaction to c1 inh products, including cinryze or other blood products. * history of abnormal blood clotting. * have a known allergy to hyaluronidase or any other ingredient in the study formulation.

Keywords: crossover c1 esterase inhibitor prevention c1 inhibitor hereditary angioedema subcutaneous recombinant human hyaluronidase
study on clinical prognosis, risk factors and genetic basis of congenital heart disease

Conditions: Congenital Heart Disease

Summary: the objective of this study is to investigate the effect of parental peri-natal environmental risk factors and genetic factors on the development of congenital heart disease (chd). our hypothesis is that the distributions of some environmental and genetic risk factors significantly differ between neonates with and without chd.

congenital heart defect (chd) is one of birth defects in the structure of the heart and/or great vessels. many types of heart defects exist, most of which either obstruct blood flow in the heart or vessels near it, or cause blood to flow through the heart in an abnormal pattern. heart defects are the leading cause of birth defect-related infant deaths. so far people recognize that the causes of chd are the conjunct effect of environment and genetic factors, both of which remain unclear. the current stud aims at investigating all the possible perinatal parental environmental risk factors and underlying genetic factors to chd, including dna variation and methylations. a hospital-based 1:1 matched case control study is conducted. subjects were recruited through neonatal screening program, which includes a clinical symptom screening followed by a cardiac ultrasound diagnosis for those with at least one clinical indicator. the blood sample of participant will be collected and the parents of subjects will be interviewed to completed a questionnaire including general information and possible risk factors to chd.

Eligibility criteria:
case group inclusion criteria: * han ethnic * 0\~3 years old * screened by 7 indicator, diagnosed by ultrasound exclusion criteria: * with other brith defects * with patent ductus arteriosus (pda) and patent foramen ovale (pfo) control group inclusion criteria: * han ethnic * 0\~3 years old * without any of 7 screen indicator , without chd heart palpitations and other complaints about heart disease, born in the same hospital with cases exclusion criteria: with other birth defects

Keywords: congenital heart disease dna variation methylation risk factors supplements
bay38-9456 (vardenafil hcl tablet) in ed treatment for china registration.

Conditions: Erectile Dysfunction

Summary: this study was to compare the efficacy of 3 doses of vardenafil, 5 mg, 10 mg and 20 mg, with matching placebo in chinese male ed patients, treated for a maximum of 12 weeks.


Eligibility criteria:
inclusion criteria: * men with ed for more than 6 months. ed defined according to the national institute of health, usa department of health and human services, consensus statement, as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance. * stable heterosexual relationship exclusion criteria: * primary hypoactive sexual desire- history of myocardial infarction, stroke or life-threatening arrhythmia within the 6-month period prior to visit 1 (week -4) * nitrate use * other exclusion criteria apply

Keywords: male erectile dysfunction
adolescent idiopathic scoliosis (ais) patient positioning in eos system®

Conditions: Adolescent Idiopathic Scoliosis

Summary: the eos® imaging system, a new imaging modality which offers low dose, weight bearing and full body x-ray imaging, requires a new standing position where patients put their hands and forearms on the wall vertically for stability. although this method provides enough support for the patients during the extended x-ray acquisition time, its impact on the postural balance and sagittal profile of the spine and sacro-pelvic parameters has not been evaluated. the goal of this study is to identify the impact of patients' arm positioning on the sagittal profile and postural balance of the patient and subsequently propose a standardized method for full spine x-ray acquisition in the eos® imaging system.

spino-pelvic sagittal analysis and postural assessment are important parameters in adolescent idiopathic scoliosis (ais) treatment and surgical planning.the three-dimensional (3d) shape of the spine is impacted by the patients' posture particularly in adolescents with flexible spinal curves. the latter highlights the importance of the patients' positioning during x-ray acquisition in order to avoid any misleading measurements that may adversely impact monitoring and surgical curve correction in ais. participating subjects will undergo two bi-planar x-rays in different positions. the positions will be instructed by the means of graphical presentation and verbal explanation by the radiology technician. the first standing position in the eos® imaging system for full spinal x-ray acquisition will consist of putting both hands and forearms in front of the subject on the wall vertically. in the second position, knuckles are loosely placed on ipsi-lateral clavicles. bi-planar x-rays will be taken in the eos® imaging system for both positions. moreover to compare the postural balance of the patient in the two described positions, a pressure mat will be placed in the eos® system. the pressure mat will be calibrated with the eos® system and permits to identify the position of the center of pressure (cop) with respect to the anatomical landmarks. the magnitude of pressure under the patients' feet will be measured during each x-ray and compared.

Eligibility criteria:
inclusion criteria: * subjects age 10-18 * diagnosis of adolescent idiopathic scoliosis * prescribed bi-planar full spine x-ray images * must be able to stand still for 10 seconds without any support * must be able to follow verbal and visual instruction exclusion criteria: * previous surgical treatment * diagnosis of a neuro-muscular disorder * have supernumerary vertebrae, congenital deformities, spondylolisthesis, or spina bifida * have any other musculoskeletal disorder that impacts standing balance such as hip, knee, ankle pain and instability or lower back pain * bmi higher than 30 * pregnant or lactating females * parents/guardians or subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures

Keywords: scoliosis postural balance lordosis kyphosis x-rays